- Exchange: NASDAQ GS
- Sector: Health Care
- Industry: Biotech & Pharma
- Sub-Industry: Biotech
BioCryst Pharmaceuticals Inc
+ Add to WatchlistBCRX:US
1.7000 USD 0.0200 1.19%As of 20:10:00 ET on 06/17/2013.
Snapshot for BioCryst Pharmaceuticals Inc (BCRX)
| Open: | 1.7000 | Day's Range: | 1.6700 - 1.7100 | Volume: | 295,497 |
|---|---|---|---|---|---|
| Previous Close: | 1.6800 | 52wk Range: | 1.0800 - 4.9500 | 1-Yr Rtn: | -55.38% |
Key Statistics for BCRX
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (USD) (ttm) | -0.7200 |
| Est. EPS (USD) (12/2013) | -0.4670 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 90.35 |
| Shares Outstanding (M) | 53.15 |
| 30 Day Average Volume | 793,359 |
| Price/Book (mrq) | - |
| Price/Sale (ttm) | 4.8650 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/06/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for BCRX
Company Profile & Key Executives for BCRX
BioCryst Pharmaceuticals, Inc. designs, optimizes and develops small-molecule novel pharmaceuticals that block key enzymes involved in infectious diseases, inflammatory diseases & cancer. The Company has late-stage compounds in development & continues to discover additional compounds & to progress them to meet the unmet medical needs of patients and physicians.
| Jon P StonehousePresident/CEO | Thomas R Staab II "Tom"Senior VP/CFO/Acctg Officer |
| William P SheridanSenior VP/Chief Medical Ofcr | Yarlagadda S BabuVP:Drug Discovery |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
BCRX News
-
Industry News
Advertisement
- 1
- 2
- 3
- 4
- 5
Advertisement
Sponsored Links
Advertisements
Rate this Page